$MLSS

Milestone Scientific (MLSS) reported a narrowed net loss of $0.84 million in Q1 2026, primarily due to sharply reduced operating expenses and a pause in R&D. Despite this improvement and positive operating cash flow, the company faces substantial doubt about its ability to continue as a going concern, evidenced by an accumulated deficit of $134.6 million and limited cash reserves. Additionally, MLSS remains below NYSE American listing thresholds, with a compliance deadline of April 2027, and its recent $2.15 million private placement introduced further dilution risks for existing shareholders.